Litigation Details for Acerta Pharma B.V. v. Pharmacyclics LLC (D. Del. 2018)
✉ Email this page to a colleague
Acerta Pharma B.V. v. Pharmacyclics LLC (D. Del. 2018)
| Docket | ⤷ Sign Up | Date Filed | 2018-04-18 |
| Court | District Court, D. Delaware | Date Terminated | 2019-10-23 |
| Cause | 35:271 Patent Infringement | Assigned To | Richard Gibson Andrews |
| Jury Demand | Plaintiff | Referred To | |
| Parties | JANSSEN BIOTECH, INC. | ||
| Patents | 7,459,554 | ||
| Attorneys | John V. Gorman | ||
| Firms | Morris, Nichols, Arsht & Tunnell | ||
| Link to Docket | External link to docket | ||
Small Molecule Drugs cited in Acerta Pharma B.V. v. Pharmacyclics LLC
The small molecule drug covered by the patent cited in this case is ⤷ Sign Up .
Details for Acerta Pharma B.V. v. Pharmacyclics LLC (D. Del. 2018)
| Date Filed | Document No. | Description | Snippet | Link To Document |
|---|---|---|---|---|
| 0000-00-00 | External link to document | |||
| 2018-04-18 | 1 | remedy for Defendants’ infringement of U.S. Patent No. 7,459,554 through the manufacture, offer to sell, …Office issued U.S. Patent No. 7,459,554, entitled “Imidazopyrazine Tyrosine Kinase Inhibitors” (Ex. A… (Infringement of U.S. Patent No. 7,459,554) 31. On information and belief… 1. This is an action for patent infringement under the patent laws of the United States, Title…practice patents relating to compounds that inhibit tyrosine kinases, including the ’554 patent. The active | External link to document | |
| 2019-10-23 | 107 | Patent/Trademark Report to Commissioner of Patents | the Commissioner of Patents and Trademarks for Patent/Trademark Number(s) 7,459,554. (Attachments: # 1 …2018 23 October 2019 1:18-cv-00581 830 Patent Plaintiff District Court, D. Delaware | External link to document |
| 2018-04-18 | 3 | the Commissioner of Patents and Trademarks for Patent/Trademark Number(s) 7,459,554. (ceg) (Entered: 04…2018 23 October 2019 1:18-cv-00581 830 Patent Plaintiff District Court, D. Delaware | External link to document | |
| 2018-11-26 | 51 | that Imbruvica infringes U.S. Patent No. 7,459,554 (the “’554 Patent”), and seeking damages for sales…seeking a declaration that U.S. Patent No. 8,399,645 (“the ’645 patent”), which St. Jude owns, is invalid…not and will not infringe the ’645 patent and that the ’645 patent is invalid”, Novartis Mot. at 4; …defending Imbruvica against Plaintiffs’ claims of patent infringement, Defendants and Janssen are differently… Imbruvica infringes a single claim of the ’554 Patent under the DOE. See D.I. 1. PCYC and AbbVie moved | External link to document | |
| >Date Filed | >Document No. | >Description | >Snippet | >Link To Document |
